StockNews.com Lowers Omnicell (NASDAQ:OMCL) to Hold

StockNews.com lowered shares of Omnicell (NASDAQ:OMCL) from a buy rating to a hold rating in a research note published on Thursday morning.

OMCL has been the subject of a number of other reports. Benchmark reissued a buy rating and issued a $38.00 price target on shares of Omnicell in a report on Monday, July 15th. Wells Fargo & Company increased their price target on shares of Omnicell from $26.00 to $30.00 and gave the stock an equal weight rating in a report on Friday, August 2nd. Bank of America upped their price objective on shares of Omnicell from $34.00 to $44.00 and gave the stock a buy rating in a research report on Friday, August 2nd. Barclays upgraded Omnicell from an underweight rating to an equal weight rating and raised their target price for the company from $26.00 to $39.00 in a research report on Friday, August 2nd. Finally, JPMorgan Chase & Co. upped their price target on Omnicell from $26.00 to $37.00 and gave the stock a neutral rating in a report on Friday, August 23rd. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of Hold and an average target price of $37.83.

Omnicell Price Performance

NASDAQ OMCL opened at $44.62 on Thursday. The stock’s fifty day moving average price is $39.21 and its 200 day moving average price is $32.28. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.45 and a quick ratio of 2.22. The company has a market cap of $2.05 billion, a price-to-earnings ratio of -97.00, a PEG ratio of 49.47 and a beta of 0.83. Omnicell has a 1 year low of $25.12 and a 1 year high of $53.37.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.37. The firm had revenue of $276.80 million during the quarter, compared to analysts’ expectations of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The firm’s revenue was down 7.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.29 earnings per share. As a group, equities research analysts forecast that Omnicell will post 0.64 earnings per share for the current year.

Institutional Trading of Omnicell

Large investors have recently made changes to their positions in the company. Federated Hermes Inc. lifted its holdings in Omnicell by 1,113.6% in the 2nd quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock valued at $26,830,000 after purchasing an additional 909,480 shares in the last quarter. Pacer Advisors Inc. raised its position in shares of Omnicell by 32.6% in the second quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock valued at $56,047,000 after buying an additional 508,789 shares during the last quarter. Norges Bank purchased a new position in shares of Omnicell in the fourth quarter worth about $18,802,000. Vanguard Group Inc. boosted its position in Omnicell by 8.5% during the fourth quarter. Vanguard Group Inc. now owns 5,571,420 shares of the company’s stock worth $209,653,000 after acquiring an additional 434,336 shares during the last quarter. Finally, Champlain Investment Partners LLC grew its stake in Omnicell by 16.0% during the 1st quarter. Champlain Investment Partners LLC now owns 1,753,205 shares of the company’s stock valued at $51,246,000 after acquiring an additional 241,235 shares in the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.